Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Inmed Pharmaceuticals Inc (NQ: INM ) 0.2742 +0.0002 (+0.07%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 5, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Inmed Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 8 Next > InMed Pharmaceuticals Is Commercializing The Development Of Rare Cannabinoids For The Wellness Market May 17, 2022 Upon its acquisition of BayMedica LLC last year, InMed Pharmaceuticals Inc. (Nasdaq: INM) made the executive decision to forge a new path alongside its traditional domain in pharmaceutical drug... Via Benzinga InMed Pharmaceuticals Reports Net Sales Of $575K For 6 Months Since BayMedica Acquisition May 13, 2022 InMed Pharmaceuticals Inc. (NASDAQ:INM), a leader in research, development, manufacturing and commercialization of rare cannabinoids, released unaudited financial results for the third quarter of the... Via Benzinga InMed Commercializes Rare Cannabinoids For Health And Wellness Market May 09, 2022 This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday May 03, 2022 It's time for another dive into the biggest pre-market stock movers for today as we prepare for a busy day of trading on Tuesday! Via InvestorPlace InMed Pharmaceuticals' Issues Annual Shareholder Letter January 05, 2022 InMed Pharmaceuticals (NASDAQ: Via Benzinga 20 Stocks Moving in Tuesday's Pre-Market Session May 03, 2022 Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares rose 38% to $3.69 in pre-market trading. Sonoma Pharmaceuticals and MicroSafe Group DMCC reported EPA approval for... Via Benzinga 66 Biggest Movers From Yesterday May 03, 2022 Gainers Better Therapeutics, Inc. (NASDAQ: BTTX) shares surged 120.4% to close at $2.01 on Monday following a 5% drop on Friday. SoundHound AI, Inc. (NASDAQ: SOUN) shares surged... Via Benzinga 18 Stocks Moving in Tuesday's Pre-Market Session April 26, 2022 Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:... Via Benzinga InMed Pharmaceuticals (NASDAQ: INM) Announces Expansion Of Rare Cannabinoid Portfolio April 22, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga InMed Pharmaceuticals (NASDAQ: INM) Announces Participation In Upcoming Conferences April 20, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga InMed Pharmaceuticals Committed To Growing Market Reach, Product Portfolio March 28, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga InMed Pharmaceuticals Makes Changes In Management March 18, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga 63 Biggest Movers From Yesterday March 25, 2022 Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares gained 39.1% to close at $1.05 on Thursday. The company recently said its CFO Bruce Colwill will retire. Global Internet... Via Benzinga InMed Launching Additional Rare Cannabinoids In Response To Demand March 17, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga InMed Pharmaceuticals Expanding Portfolio In Rare Cannabinoid Market March 04, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga Stocks That Hit 52-Week Lows On Wednesday March 02, 2022 Wednesday's session saw 107 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: Citigroup (NYSE:C) was the largest company by... Via Benzinga InMed's Evolution To Commercial Sales Featured In Research Report February 17, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga InMed Names BayMedica VP Of Sales, Releases Q2 2022 Report February 16, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... Via Benzinga InMed Positioned To Offer Rare Cannabinoid Manufacturing Technologies February 15, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... Via Benzinga InMed Pharmaceuticals To Release Q2 Financial Report, Update February 11, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... Via Benzinga InMed Pharmaceuticals Strengthens Leading Role In Rare Cannabinoid Market February 04, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Cannabicitran is the first of four new rare cannabinoids InMed... Via Benzinga InMed Pharmaceuticals Defining Value Of Rare Cannabinoids In Pharma Space February 03, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Via Benzinga InMed Pharmaceuticals Expands Rare Cannabinoid Product Portfolio to Launch CBT January 20, 2022 This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. InMed Pharmaceuticals (NASDAQ: INM), a... Via Benzinga 4 Penny Stocks Insiders Are Buying January 07, 2022 When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intereste... Via Benzinga InMed Pharmaceuticals to Present at Tribe Public's Webinar Event December 30, 2021 InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing, and commercialization of rare cannabinoids, today announced that its CEO Eric A. Adams, SVP and... Via Benzinga InMed Pharmaceuticals Announces Publication of Article on CBN as Possible Glaucoma Treatment December 20, 2021 InMed Pharmaceuticals (NASDAQ: Via Benzinga InMed Pharmaceuticals' Study Marks First Phase 2 Trial to Evaluate Cannabinol for Disease Treatment December 10, 2021 InMed Pharmaceuticals (NASDAQ: INM) recently released its Q1 2022 financial results along with a business update showing positive momentum across all of its programs. Following... Via Benzinga InMed Pharmaceuticals Targeting Potential Therapeutics Addressing Unmet Needs December 01, 2021 InMed Pharmaceuticals (NASDAQ: INM) recently filed a Patent Cooperation Treaty (“PCT”) application, which specifies a rare cannabinoid (new to InMed’s portfolio... Via Benzinga Topics Intellectual Property Exposures Intellectual Property InMed Pharmaceuticals Releases Q1 2022 Financial Results, Business Update November 29, 2021 InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 November 29, 2021 Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE: Via Benzinga < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.